{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T15:46:16Z","timestamp":1793029576615,"version":"4.5.0"},"reference-count":22,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,12,17]],"date-time":"2025-12-17T00:00:00Z","timestamp":1765929600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004325","name":"AstraZeneca PLC","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004325","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["esmoopen.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["ESMO Open"],"published-print":{"date-parts":[[2026,2]]},"DOI":"10.1016\/j.esmoop.2025.106049","type":"journal-article","created":{"date-parts":[[2026,1,21]],"date-time":"2026-01-21T20:17:59Z","timestamp":1769026679000},"page":"106049","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"title":["Camizestrant in combination with capivasertib for women with ER-positive, HER2-negative advanced breast cancer: results from SERENA-1"],"prefix":"10.1016","volume":"11","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9919-2748","authenticated-orcid":false,"given":"C.","family":"Vaklavas","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9152-8799","authenticated-orcid":false,"given":"M.","family":"Oliveira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.C.","family":"Armstrong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5027-6388","authenticated-orcid":false,"given":"I.","family":"Moreno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Twelves","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8733-6089","authenticated-orcid":false,"given":"I.","family":"Victoria Ruiz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B.","family":"Bermejo de las Heras","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T.","family":"Brier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0809-2136","authenticated-orcid":false,"given":"C.","family":"Ciardullo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"Gibbons","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T.","family":"Jack","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T.","family":"Klinowska","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1531-9754","authenticated-orcid":false,"given":"J.P.O.","family":"Lindemann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.M.","family":"Mathewson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"Maudsley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.J.","family":"Morrow","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Sykes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.D.","family":"Baird","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"6","key":"10.1016\/j.esmoop.2025.106049_bib1","first-page":"477","article-title":"Breast cancer statistics 2024","volume":"74","author":"Giaquinto","year":"2024","journal-title":"CA Cancer J Clin"},{"issue":"3","key":"10.1016\/j.esmoop.2025.106049_bib2","first-page":"229","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray","year":"2024","journal-title":"CA Cancer J Clin"},{"issue":"5","key":"10.1016\/j.esmoop.2025.106049_bib3","first-page":"480","article-title":"Systemic therapy for hormone receptor-positive\/human epidermal growth factor receptor 2-negative early stage and metastatic breast cancer","volume":"73","author":"Huppert","year":"2023","journal-title":"CA Cancer J Clin"},{"issue":"1","key":"10.1016\/j.esmoop.2025.106049_bib4","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1038\/s41523-023-00523-4","article-title":"An emerging generation of endocrine therapies in breast cancer: a clinical perspective","volume":"9","author":"Patel","year":"2023","journal-title":"NPJ Breast Cancer"},{"key":"10.1016\/j.esmoop.2025.106049_bib5","article-title":"Molecular mechanisms of endocrine resistance in estrogen-positive breast cancer","volume":"12","author":"Belachew","year":"2021","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"1","key":"10.1016\/j.esmoop.2025.106049_bib6","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1186\/s13058-021-01462-3","article-title":"ESR1 mutation as an emerging clinical biomarker in metastatic hormone receptor-positive breast cancer","volume":"23","author":"Brett","year":"2021","journal-title":"Breast Cancer Res"},{"issue":"15","key":"10.1016\/j.esmoop.2025.106049_bib7","doi-asserted-by":"crossref","first-page":"7812","DOI":"10.3390\/ijms22157812","article-title":"Oral selective estrogen receptor degraders (SERDs) as a novel breast cancer therapy: present and future from a clinical perspective","volume":"22","author":"Hernando","year":"2021","journal-title":"Int J Mol Sci"},{"issue":"23","key":"10.1016\/j.esmoop.2025.106049_bib8","doi-asserted-by":"crossref","first-page":"3989","DOI":"10.1158\/0008-5472.CAN-23-0694","article-title":"The next-generation oral selective estrogen receptor degrader camizestrant (AZD9833) suppresses ER+ breast cancer growth and overcomes endocrine and CDK4\/6 inhibitor resistance","volume":"83","author":"Lawson","year":"2023","journal-title":"Cancer Res"},{"issue":"16","key":"10.1016\/j.esmoop.2025.106049_bib9","doi-asserted-by":"crossref","first-page":"4242","DOI":"10.1158\/1078-0432.CCR-19-3387","article-title":"A randomized, open-label, presurgical, window-of-opportunity study comparing the pharmacodynamic effects of the novel oral SERD AZD9496 with fulvestrant in patients with newly diagnosed ER(+) HER2(-) primary breast cancer","volume":"26","author":"Robertson","year":"2020","journal-title":"Clin Cancer Res"},{"issue":"8","key":"10.1016\/j.esmoop.2025.106049_bib10","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1016\/j.annonc.2024.04.012","article-title":"A phase I dose escalation and expansion trial of the next-generation oral SERD camizestrant in women with ER-positive, HER2-negative advanced breast cancer: SERENA-1 monotherapy results","volume":"35","author":"Hamilton","year":"2024","journal-title":"Ann Oncol"},{"issue":"20","key":"10.1016\/j.esmoop.2025.106049_bib11","doi-asserted-by":"crossref","first-page":"4244","DOI":"10.1158\/1078-0432.CCR-25-1198","article-title":"Camizestrant in combination with three globally approved CDK4\/6 inhibitors in women with ER+, HER2- advanced breast cancer: results from SERENA-1","volume":"31","author":"Baird","year":"2025","journal-title":"Clin Cancer Res"},{"issue":"11","key":"10.1016\/j.esmoop.2025.106049_bib12","doi-asserted-by":"crossref","first-page":"1424","DOI":"10.1016\/S1470-2045(24)00387-5","article-title":"Camizestrant, a next-generation oral SERD, versus fulvestrant in post-menopausal women with oestrogen receptor-positive, HER2-negative advanced breast cancer (SERENA-2): a multi-dose, open-label, randomised, phase 2 trial","volume":"25","author":"Oliveira","year":"2024","journal-title":"Lancet Oncol"},{"issue":"6","key":"10.1016\/j.esmoop.2025.106049_bib13","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1056\/NEJMoa2502929","article-title":"First-line camizestrant for emerging ESR1-mutated advanced breast cancer","volume":"393","author":"Bidard","year":"2025","journal-title":"N Engl J Med"},{"issue":"22","key":"10.1016\/j.esmoop.2025.106049_bib14","doi-asserted-by":"crossref","first-page":"2058","DOI":"10.1056\/NEJMoa2214131","article-title":"Capivasertib in hormone receptor-positive advanced breast cancer","volume":"388","author":"Turner","year":"2023","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.esmoop.2025.106049_bib15","doi-asserted-by":"crossref","first-page":"16","DOI":"10.3390\/cancers17010016","article-title":"New emerging therapies targeting PI3K\/AKT\/mTOR\/PTEN pathway in hormonal receptor-positive and HER2-negative breast cancer-current state and molecular pathology perspective","volume":"17","author":"Liu","year":"2024","journal-title":"Cancers (Basel)"},{"issue":"1","key":"10.1016\/j.esmoop.2025.106049_bib16","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1186\/s12943-023-01827-6","article-title":"PI3K\/AKT\/mTOR signaling transduction pathway and targeted therapies in cancer","volume":"22","author":"Glaviano","year":"2023","journal-title":"Mol Cancer"},{"issue":"12","key":"10.1016\/j.esmoop.2025.106049_bib17","doi-asserted-by":"crossref","first-page":"1450","DOI":"10.1200\/JCO.24.00248","article-title":"Endocrine and targeted therapy for hormone receptor-positive, human epidermal growth factor receptor 2-negative metastatic breast cancer-capivasertib-fulvestrant: ASCO rapid recommendation update","volume":"42","author":"Burstein","year":"2024","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.esmoop.2025.106049_bib19","doi-asserted-by":"crossref","DOI":"10.1111\/cts.70475","article-title":"Open-label study assessing relative and absolute bioavailability of oral camizestrant formulations and food effects in healthy postmenopausal women","author":"Sykes","year":"2026","journal-title":"Clin Trans Sci"},{"issue":"8","key":"10.1016\/j.esmoop.2025.106049_bib20","doi-asserted-by":"crossref","first-page":"1191","DOI":"10.1007\/s40262-024-01407-x","article-title":"Population pharmacokinetics of capivasertib in patients with advanced or metastatic solid tumours","volume":"63","author":"Fernandez-Teruel","year":"2024","journal-title":"Clin Pharmacokinet"},{"issue":"15","key":"10.1016\/j.esmoop.2025.106049_bib21","doi-asserted-by":"crossref","first-page":"3947","DOI":"10.1158\/1078-0432.CCR-19-3953","article-title":"Capivasertib, an AKT kinase inhibitor, as monotherapy or in combination with fulvestrant in patients with AKT1 (E17K)-mutant, ER-positive metastatic breast cancer","volume":"26","author":"Smyth","year":"2020","journal-title":"Clin Cancer Res"},{"issue":"1","key":"10.1016\/j.esmoop.2025.106049_bib22","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1038\/s41523-021-00251-7","article-title":"Selective AKT kinase inhibitor capivasertib in combination with fulvestrant in PTEN-mutant ER-positive metastatic breast cancer","volume":"7","author":"Smyth","year":"2021","journal-title":"NPJ Breast Cancer"},{"issue":"9","key":"10.1016\/j.esmoop.2025.106049_bib23","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2024.103697","article-title":"Capivasertib and fulvestrant for patients with hormone receptor-positive advanced breast cancer: characterization, time course, and management of frequent adverse events from the phase III CAPItello-291 study","volume":"9","author":"Rugo","year":"2024","journal-title":"ESMO Open"}],"container-title":["ESMO Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2059702925019192?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2059702925019192?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,2,23]],"date-time":"2026-02-23T16:28:29Z","timestamp":1771864109000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2059702925019192"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2]]},"references-count":22,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,2]]}},"alternative-id":["S2059702925019192"],"URL":"https:\/\/doi.org\/10.1016\/j.esmoop.2025.106049","relation":{},"ISSN":["2059-7029"],"issn-type":[{"value":"2059-7029","type":"print"}],"subject":[],"published":{"date-parts":[[2026,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Camizestrant in combination with capivasertib for women with ER-positive, HER2-negative advanced breast cancer: results from SERENA-1","name":"articletitle","label":"Article Title"},{"value":"ESMO Open","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.esmoop.2025.106049","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Author(s). Published by Elsevier Ltd on behalf of European Society for Medical Oncology.","name":"copyright","label":"Copyright"}],"article-number":"106049"}}